Company: VCYT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001384101-25-000051
Chunk: 31

Company: VERACYTE, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 31
---
 we compete for talent and has been well within investor expectations historically.

The burn rate figures included below are based on equity awards granted under our 2023 Plan and our 2013 Plan, and exclude potential dilution resulting from shares issued pursuant to our Amended and Restated Employee Stock Purchase Plan (the “ESPP”). As we continue to mature our compensation practices, we strive to achieve a burn rate and overhang at approximately the average rates of our peer group, and that are within the limits recommended by certain independent stockholder advisory groups.

| Fiscal Year |     | Granted Appreciation Awards (Options and SARs) 
 (#)(1)                                         |           |     | Granted Full-Value Awards (RSUs) 
 (#)(2)                           |           |     | Weighted Common Stock Outstanding as of December 31of the applicable year 
 (#)                                                                       |            |     |      | Burn Rate 
 (%)       |
| 2022        |     |                                                | 1,132,620 |     |                                  | 1,746,249 |     |                                                                           | 71,549,204 |     | 4.02 |           |
| 2023        |     |                                                |   660,592 |     |                                  | 1,767,312 |     |                                                                           | 72,644,487 |     | 3.34 |           |
| 2024        |     |                                                |         — |     |                                  | 2,220,157 |     |                                                                           | 76,484,759 |     | 2.90 |           |

(1) All options granted during 2022, 2023 and 2024 included a time-based vesting schedule.

(2) Includes both time-based RSUs and PSUs (assuming target-level achievement) granted during 2022, 2023 and 2024.

#### Veracyte2025 Proxy Statement31

#### Proposal Five

#### Potential Dilution
As of March 31, 2025:

• There were 78,306,356 total shares of our common stock outstanding.

• The closing market price of our common stock on March 31, 2025 was $29.65.

• The company’s outstanding stock options have a weighted average per share exercise price of $25.36 and a weighted average remaining contractual term of 5.1 years.

• The following table shows outstanding equity awards granted and outstanding under the 2023 Plan and our 2013 Plan, and